Health Condition 1: C61- Malignant neoplasm of prostate
Conditions
Interventions
Intervention1: Ga68-PSMA PETCT: To measure the volumetric and spatial concordance between the DIL volume as delineated on the prostate multiparametric MRI (mpMRI) and RT planning Ga68-PSMA PETCT scans
Sponsors
Varian Medical System
Eligibility
Inclusion criteria
Inclusion criteria: 1 Histological diagnosis of adenocarcinoma prostate 2 Suitableand planned for stereotactic body radiotherapy (SBRT) to the prostate 3 Visible DIL in both mpMRI and Ga68-PSMA PETCT scans done not more than four weeks apart
Exclusion criteria
Exclusion criteria: 1 More than four weeks of androgen deprivation therapy or cancer-directed systemic therapy before baseline imaging 2 Inability to deliver adequate radiotherapy dose safely based on assessment by radiation oncologist 3 IPSS >20 4 Prior TURP within 3 months 5 Urethral stricture 6 Prostate gland volume >80cc 7 cT4 (AJCC 8th) 8 Untreated anal hemorrhoids/fissures 9 Pt unable to consent 10 Patients unwilling or unreliable for regular follow-up and surveillance imaging
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To measure the volumetric and spatial concordance between the DIL volume as delineated on the prostate multiparametric MRI (mpMRI) and RT planning Ga68-PSMA PETCT scansTimepoint: baseline radiotherapy planning | — |
Secondary
| Measure | Time frame |
|---|---|
| To determine a suitable threshold for auto-contouring of the DIL volume in Ga68-PSMA PETCT Response assessment post radiotherapyTimepoint: Baseline radiotherapy planning, then every 3 months after completing radiotherapy, till total two years | — |
Countries
India
Contacts
Public ContactDr Vedang Murthy
ACTREC, Tata Memorial Centre
Outcome results
None listed